Skip to content

Randomized parallel controlled study/project of Ruyi Zhenbao Pills in the treatment of patients with chronic gouty arthritis

Randomized parallel controlled study/project of Ruyi Zhenbao Pills in the treatment of patients with chronic gouty arthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001151
Enrollment
Unknown
Registered
2025-06-12
Start date
2025-06-19
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic gouty arthritis

Interventions

control group:No taking Ruyi Zhenbao pills
treatment group:taking Ruyi Zhenbao pills (4 pills at a time 2 times a day)

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) The research subjects met the 2015 ACR/EULAR diagnostic criteria for gouty arthritis and the 2004 Guidelines for the Diagnosis and Treatment of Primary Gout (Draft) and the Guidelines for the Diagnosis and Treatment of Primary Gout (Draft) Key Points for the diagnosis of CGA: the course of the disease has been prolonged for many years the consequences of continuous high concentration of blood uric acid have not been satisfactorily controlled and the characteristics of this stage are the characteristics of tophi formation or continuous failure to relieve joint symptoms. (2) The TCM syndrome type belongs to the damp heat poison accumulation pattern or phlegm stasis obstruction pattern or spleen deficiency and damp heat pattern. (3) Age between 18-80 years old gender is not limited. (4) Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: Potential subjects who meet the inclusion criteria will be excluded if they meet any of the following: (1) Patients with severe cardiovascular brain lung liver kidney hematopoietic system diseases malignant tumors and mental diseases. (2) Women who are pregnant or breastfeeding. (3) Patients with active gastroduodenal ulcer or gastritis caused by long-term use of non-steroidal anti-inflammatory drugs. (4) Patients with underlying diseases or secondary gout caused by the use of drugs.

Design outcomes

Primary

MeasureTime frame
Number of acute gouty arthritis attacks;

Secondary

MeasureTime frame
The interval between gout attacks;Duration of gout attack;Joint color ultrasound;Blood uric acid level;VAS score of gout attack;The location and number of joints at the time of the gout attack;Erythrocyte sedimentation rate;Frequency of recurrence of gout attacks;C-reactive protein;A scoring scale for TCM syndromes;Health Assessment Questionnaire Disability Index-HAQ-DI;

Countries

China

Contacts

Public ContactHuangRunyue

Guangdong Provincial Hospital of Chinese Medicine

ryhuang@gzucm.edu.cn15889932190

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026